Feb 20 2026 This Week in Cardiology
This Week in Cardiology
Medscape Podcasts
4.9 • 963 Ratings
🗓️ 20 February 2026
⏱️ 25 minutes
🧾️ Download transcript
Summary
EVOLUT Low Risk data, a provocative meta-analysis, DNR orders, targeted hypothermia, good news in HFpEF evidence, and GLP-1s as AF drugs are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I EVOLUT Low Risk 6-year Results and a 5-year Meta-Analysis of TAVR vs SAVR
- 6-Year Outcomes of TAVR vs SAVR https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063
- EVOLUT Low Risk Trial at 2 years https://www.nejm.org/doi/full/10.1056/NEJMoa1816885
- EVOLUT Low Risk Trial at 3 years https://www.jacc.org/doi/10.1016/j.jacc.2023.02.017
- EVOLUT Low Risk Trial at 4 years https://www.jacc.org/doi/10.1016/j.jacc.2023.09.813
- Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials https://www.jacc.org/doi/10.1016/j.jacc.2019.08.1034
- TAVR vs SAVR 5-Year Outcomes - Systematic Review https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092
- TAVR vs SAVR Updated Meta-Analysis of RCTs https://www.jacc.org/doi/10.1016/j.jacc.2024.12.031
- UK TAVI Trial https://jamanetwork.com/journals/jama/fullarticle/2792251
- Dr David Cohen on X https://x.com/djc795/status/2023556582030852172?s=46&t=zXMCUoVjSsdyemzWlzeBjA
II DNR in the Hospital
- Inadequate Documentation of Unilateral DNR Orders https://jamanetwork.com/journals/jama/fullarticle/2829203
- GeriPal Blog Unilateral DNR Orders https://geripal.org/unilateral-dnr-gina-piscitello-erin-demartino-will-parker/
III Yet another failure of Targeted Hypothermia
- 2-Year Follow-Up of TTM2 Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2845193
- TTM2 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2100591
IV Good news in HFpEF Evidence
- ALT-FLOW II Trial https://doi.org/10.1093/ejhf/xuaf016
V GLP-1 as AF drugs
- Semaglutide as Adjunctive Therapy in Obesity-Related PAF https://doi.org/10.1093/europace/euag018
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Transcript
Click on a timestamp to play from that location
| 0:00.0 | You're listening to This Week in Cardiology from the heart.org, Medscape Cardiology. |
| 0:05.4 | This podcast is intended for health care professionals only. Any views expressed are the |
| 0:10.0 | presenters own and do not necessarily reflect the views of WebMD or Medscape. |
| 0:14.7 | Hi, everyone. This is John Mandrola from the Heart.org Medscape Cardiology, and this is this |
| 0:20.2 | week in cardiology for February 20th, |
| 0:22.7 | 2026. This week, longer-term data and evolute low-risk tavi trial, a provocative meta-analysis, |
| 0:30.8 | DNR, targeted hypothermia, good news and hefpeth evidence, GLP1 agents as AFIB drugs, any evaluation of patients with chest pain. |
| 0:42.0 | There was big news in the Tavi versus SAVER in low-risk patients this week. |
| 0:46.9 | Jack published six-year outcomes of the Evalute Low-Risk trial, and there were surprises. |
| 0:54.2 | Now, recall that the Evalute Low Risk was first published in the New England Journal Medicine in 2019. |
| 1:00.6 | This had 1,468 patients with severe AS, and they were randomized to the self-expanding Medtronic Tavi valve versus surgical AVR. |
| 1:12.0 | This study had a non-inferiority design with a primary endpoint of death or disabling |
| 1:16.7 | stroke at two years, and it was analyzed with Bayesian methods. |
| 1:21.8 | The trial found a greater than 99% probability that Tavi was non-inferior to |
| 1:27.3 | surgical AVR or SAVR. Now many trials have shown |
| 1:31.1 | similar outcomes for Tavi versus SAVR at two years. Low surgical risk patients, though, want to know |
| 1:37.6 | about longer duration outcomes, including the valve reliability and the intervention or re-intervention |
| 1:44.0 | rate. |
| 1:45.2 | Now, before I say anything about the results, |
| 1:47.5 | I have to say that both the balloon expandable and self-expanding trialists |
| 1:51.2 | have been excellent about reporting longer-term outcomes. |
| 1:54.6 | I mean, other than the partner three's mysterious change of primary endpoint, |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Medscape Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Medscape Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.